Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.2K
Structure and Function of Platelets01:18

Structure and Function of Platelets

4.3K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.3K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

601
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
601

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipoprotein(a)-associated proteomic signature predicts cardiovascular disease in young adults.

The Journal of clinical investigation·2026
Same author

Plasma von Willebrand Factor and ADAMTS13 Interact With <i>APOE</i>-ε4 in Predicting Longitudinal Brain Atrophy and Cognitive Decline Over a 9-Year Follow-Up.

Journal of the American Heart Association·2026
Same author

Endothelial cell expression of STING<sup>V154M</sup>: Gain-of-function mutation delays the resolution of UVB-induced skin injury.

The Journal of investigative dermatology·2026
Same author

Proteomic signatures of pediatric cardiovascular and cardiometabolic traits demonstrate long-term modifiable drivers of adult disease.

medRxiv : the preprint server for health sciences·2025
Same author

Interplay Between Thrombospondin-1 and CD36 Modulates Platelet-RBC Interaction in Thrombosis and Abdominal Aneurysm Formation.

Circulation research·2025
Same author

Pattern recognition receptor-associated immuno-thrombotic transcript changes in platelets and leukocytes with COVID19.

PLoS pathogens·2025

Related Experiment Video

Updated: Mar 9, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.3K

Thrombosis and platelets: an update.

Milka Koupenova1, Beate E Kehrel2, Heather A Corkrey1

  • 1University of Massachusetts Medical School, Albert Sherman Center, 368 Plantation St, Worcester, MA 01605, USA.

European Heart Journal
|January 1, 2017
PubMed
Summary

Understanding haemostasis and thrombosis is evolving, with new insights into vascular occlusion and inflammation. This review explores emerging risk factors for thrombosis, balancing treatment benefits against bleeding risks.

Keywords:
BleedingCardiovascularCoagulationPlateletsThrombosis

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.2K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.5K

Related Experiment Videos

Last Updated: Mar 9, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.3K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.2K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.5K

Area of Science:

  • Cardiovascular Science
  • Hematology
  • Immunology

Background:

  • Haemostasis and thrombosis are intricate processes with ongoing research into vascular occlusion mechanisms.
  • Inflammation and immunity significantly influence thrombotic events, necessitating a deeper understanding.
  • Current treatments for vascular occlusive diseases face challenges, including the risk of bleeding complications.

Purpose of the Study:

  • To review recent advancements in understanding thrombosis.
  • To examine the impact of non-thrombotic diseases on haemostasis and thrombosis.
  • To evaluate evolving risk factors contributing to thrombotic events.

Main Methods:

  • Literature review of recent scientific publications.
  • Analysis of mechanistic pathways in platelet function and thrombosis.
  • Assessment of the interplay between non-thrombotic diseases and thrombotic risk.

Main Results:

  • Significant progress has been made in elucidating platelet function and thrombosis pathways.
  • Pharmacological interventions have improved thrombotic outcomes but increased bleeding risks.
  • Non-thrombotic conditions represent critical, yet often overlooked, determinants of thrombotic risk.

Conclusions:

  • A comprehensive understanding of evolving risk factors is crucial for accurate thrombotic risk assessment.
  • Optimizing treatment strategies requires considering the influence of non-thrombotic diseases.
  • Further research is needed to integrate immune and inflammatory mechanisms into clinical practice for thrombosis management.